Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer, Xeris uses these filings to report financial results, describe product performance for Recorlev, Gvoke, and Keveyis, and update investors on developments in its pipeline and technology platforms, including XP-8121 and the XeriSol and XeriJect technologies.
Key documents for XERS include current reports on Form 8-K, which Xeris uses to furnish press releases detailing quarterly and year-to-date results, revenue by product, cost of goods sold, research and development spending, selling, general and administrative expenses, and non-GAAP measures such as Adjusted EBITDA. These filings also summarize business highlights, such as changes in demand across the company’s commercial products, updates to revenue guidance, and commentary on investments in Recorlev commercialization and pipeline advancement.
In addition to 8-Ks, investors typically consult annual reports on Form 10-K and quarterly reports on Form 10-Q for a more comprehensive view of Xeris’ business, including risk factors, segment information, and detailed financial statements. Proxy statements and other filings can provide information on governance and compensation, while ownership and insider transaction reports on forms such as Form 4 can show equity awards and trading activity by directors and officers.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand revenue trends, product performance, and key disclosures without reading every page. Real-time updates from EDGAR help ensure that new XERS filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 reports, are available as they are posted, giving investors a structured way to review Xeris’ regulatory history and ongoing reporting.
XERS filed a Form 144 reporting Rule 144 sales by Beth P. Hecht. The notice lists two 10b5-1 sales of 16,667 common shares each on
Xeris Biopharma Holdings, Inc. files its annual report describing a commercial-stage biopharma business focused on chronic endocrine and neurological diseases in the United States. As of June 30, 2025, non‑affiliate common stock had an aggregate market value of about $731.1 million, and 172,431,290 shares were outstanding as of February 27, 2026.
The company markets three main products: Recorlev$1 billion in peak annual U.S. net revenue; Gvoke, a ready‑to‑use glucagon for severe hypoglycemia with an estimated $5.0 billion U.S. addressable market; and Keveyis for primary periodic paralysis with a U.S. market potential above $0.5 billion.
Xeris highlights its lead pipeline candidate XP‑8121, a once‑weekly subcutaneous levothyroxine using its proprietary XeriSol technology, targeting a hypothyroidism peak sales opportunity of $1.0 to $3.0 billion in the United States. The report also emphasizes the company’s XeriSol and XeriJect formulation platforms, extensive global patent estate, reliance on third‑party manufacturers, and detailed U.S. regulatory, intellectual property, and compliance frameworks governing its products and development programs.
Xeris Biopharma reported record results for the fourth quarter and full year 2025 and issued strong 2026 guidance. Fourth quarter total revenue rose to $85.8 million from $60.1 million, driven by Recorlev, Gvoke and Keveyis growth, and net income reached $11.1 million versus a prior-year net loss of $5.1 million.
For 2025, total revenue increased to $291.8 million from $203.1 million, with Recorlev sales more than doubling. The company generated full-year net income of $0.6 million, a sharp improvement from a $54.8 million loss in 2024. Adjusted EBITDA improved to $59.4 million from $1.2 million, reflecting higher sales and operating leverage.
For 2026, Xeris expects total revenue between $375 million and $390 million, implying more than 30% growth at the midpoint, and projects higher R&D and SG&A to support XP-8121 Phase 3 development and Recorlev investment while increasing Adjusted EBITDA versus 2025.
Xeris Biopharma Holdings, Inc. officer Anh Tu Nguyen reported a Form 4 transaction where 29,300 shares of common stock were withheld by the company at
After this tax-withholding disposition, Nguyen directly owned 395,023 shares of common stock, with additional indirect holdings of 3,710 shares through an IRA and 3,501 shares through children’s IRAs, for which he disclaims full beneficial ownership beyond his pecuniary interest.
Xeris Biopharma Holdings, Inc. director and Chief Executive Officer Shannon John Patrick Jr reported equity compensation and related tax-withholding activity in company stock. On January 30, 2026, he received 478,436 shares of common stock for $0, issued as restricted stock units that vest in equal annual installments over three years, subject to continued employment. On the same date, he was granted 639,639 stock options with a $7.36 exercise price, also vesting in equal annual installments over three years and expiring on January 30, 2036. On January 31, 2026, the company withheld blocks of common shares at $7.36 per share to cover income tax and withholding obligations tied to vested restricted stock units. After these transactions, he directly owned 2,935,578 shares of common stock and 639,639 stock options.
Xeris Biopharma Holdings, Inc. executive equity activity: President and Chief Operating Officer Kevin McCulloch reported new stock-based compensation and related tax share withholdings. On January 30, 2026, he received 168,463 shares of common stock through a restricted stock unit grant that vests in three equal annual installments, subject to continued employment.
On the same date, he was granted 225,225 stock options with a $7.36 exercise price, also vesting in three equal annual installments, subject to continued service. On January 31, 2026, the company withheld 68,454, 30,289, and 27,319 shares at $7.36 per share to cover income tax obligations on vested restricted stock units. After these transactions, he directly owned 1,727,827 common shares.
The filing also notes 25,000 shares held indirectly by his spouse, with McCulloch disclaiming beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings reported insider equity awards and related tax share withholding for Chief Financial Officer Steven Pieper. On January 30, 2026, he received 154,986 shares of common stock through a restricted stock unit grant under the 2018 Stock Option and Incentive Plan, vesting in equal annual installments over three years, subject to continued employment.
On the same date, he was granted 207,207 stock options with an exercise price of $7.36 per share, also vesting annually over three years and expiring on January 30, 2036. On January 31, 2026, a total of 206,?
Xeris Biopharma Holdings Chief Medical Officer Nguyen Anh Tu reported new equity awards. On January 30, 2026, he received 121,293 shares of common stock through a restricted stock unit grant and 162,162 stock options with a $7.36 exercise price.
The restricted stock units and stock options each vest in equal annual installments over three years, conditioned on continued employment or service. Following the grant, he directly holds 424,323 shares of common stock and 162,162 options, plus indirect holdings of common stock through an IRA and a children's IRA, for which he disclaims beneficial ownership beyond his economic interest.
Xeris Biopharma Holdings’ Chief Legal Officer and Corporate Secretary Beth Hecht reported multiple equity transactions in XERS stock. On January 30, 2026, she received 121,293 shares of common stock via restricted stock units and a grant of 162,162 stock options under the company’s 2018 Stock Option and Incentive Plan, both vesting in equal annual installments over three years.
On January 31, 2026, a total of shares were withheld at $7.36 per share to cover taxes on vested restricted stock units. On February 2, 2026, she sold 16,667 shares of common stock at a weighted average price of $7.4487 per share pursuant to a pre-arranged Rule 10b5-1 trading plan, leaving her with 1,243,174 shares of directly owned common stock.